CDT vs CLRB

CDT Equity Inc. vs Cellectar Biosciences, Inc. — Valuation Comparison 2026

CDT

Pharmaceutical Preparations
CDT Equity Inc.
Quality
4.1
out of 10
Value Trap
27
LOW
Price
$1.04
Last close
Models
8/13
Active
VS

CLRB

Pharmaceutical Preparations
Cellectar Biosciences, Inc.
Quality
3.7
out of 10
Value Trap
27
LOW
Price
$3.14
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CDT Fair ValueCDT Upside CLRB Fair ValueCLRB Upside
Bayesian DCF Intrinsic $0.62 -40.7% $1.38 -56.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.17 -93.7%
Dynamic NAV Asset-Based $1.08 +3.9% $7.19 +129.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CDT vs CLRB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CDT vs CLRB — Which Stock Is More Undervalued?

CDT scores higher with a 4.1/10 quality rating vs CLRB's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing CDT Equity Inc. (CDT) and Cellectar Biosciences, Inc. (CLRB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CDT currently trades at $1.04 with a QOC of 4.1/10, while CLRB trades at $3.14 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).